Evidence map›Paper›PMID 30247922›Full record

ArticleMolecular pharmaceutics2018

Understanding Dissolution and Crystallization with Imaging: A Surface Point of View.

Dunja Novakovic, Antti Isomäki, Bibi Pleunis, Sara J Fraser-Miller, Leena Peltonen, Timo Laaksonen, Clare J Strachan

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Biological ActivityBiomacromolecules · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dunja NovakovicDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy , University of Helsinki , Viikinkaari 5 E , 00014 Helsinki , Finland.ORCID 0000-0003-2058-2194
Antti IsomäkiBiomedicum Imaging Unit, Faculty of Medicine , University of Helsinki , Haartmaninkatu 8 , 00014 Helsinki , Finland.
Bibi PleunisDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy , University of Helsinki , Viikinkaari 5 E , 00014 Helsinki , Finland.
Sara J Fraser-MillerDodd-Walls Center for Photonic and Quantum Technologies, Department of Chemistry , University of Otago , Dunedin 9016 , New Zealand.
Leena PeltonenDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy , University of Helsinki , Viikinkaari 5 E , 00014 Helsinki , Finland.
Timo LaaksonenLaboratory of Chemistry and Bioengineering , Tampere University of Technology , Korkeakoulunkatu 8 , 33720 Tampere , Finland.
Clare J StrachanDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy , University of Helsinki , Viikinkaari 5 E , 00014 Helsinki , Finland.ORCID 0000-0003-3134-8918

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tendency for crystallization during storage and administration is the most considerable hurdle for poorly water-soluble drugs formulated in the amorphous form. There is a need to better detect often subtle and complex surface crystallization phenomena and understand their influence on the critical quality attribute of dissolution. In this study, the interplay between surface crystallization of the amorphous form during storage and dissolution testing, and its influence on dissolution behavior, is analyzed for the first time with multimodal nonlinear optical imaging (coherent anti-Stokes Raman scattering (CARS) and sum frequency generation (SFG)). Complementary analyses are provided with scanning electron microscopy, X-ray diffraction and infrared and Raman spectroscopies. Amorphous indomethacin tablets were prepared and subjected to two different storage conditions (30 °C/23% RH and 30 °C/75% RH) for various durations and then dissolution testing using a channel flow-through device. Trace levels of surface crystallinity previously imaged with nonlinear optics after 1 or 2 days of storage did not significantly decrease dissolution and supersaturation compared to the freshly prepared amorphous tablets while more extensive crystallization after longer storage times did. Multimodal nonlinear optical imaging of the tablet surfaces after 15 min of dissolution revealed complex crystallization behavior that was affected by both storage condition and time, with up to four crystalline polymorphs simultaneously observed. In addition to the well-known α- and γ-forms, the less reported metastable ε- and η-forms were also observed, with the ε-form being widely observed in samples that had retained significant surface amorphousness during storage. This form was also prepared in the pure form and further characterized. Overall, this study demonstrates the potential value of nonlinear optical imaging, together with more established solid-state analysis methods, to understand complex surface crystallization behavior and its influence on drug dissolution during the development of amorphous drugs and dosage forms.

Indexed as

Drug LiberationChemistry, PharmaceuticalCrystallizationDrug StabilityDrug StorageIndomethacinMicroscopy, Electron, ScanningOptical ImagingSolubilitySpectroscopy, Fourier Transform InfraredTabletsIndomethacinTabletsamorphousdissolutionindomethacinnonlinear opticspolymorphismsurface crystallization

Identifiers

PMID30247922
PMCPMC6221374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.